This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Greenrose Holding Valuation

Is GNRS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GNRS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GNRS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GNRS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GNRS?

Key metric: As GNRS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for GNRS. This is calculated by dividing GNRS's market cap by their current book value.
What is GNRS's PB Ratio?
PB Ratio	n/a
Book	US$14.53m
Market Cap	US$1.77k

GNRS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does GNRS's PB Ratio compare to its peers?

The above table shows the PB ratio for GNRS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.000007x
INLB Item 9 Labs	0.00001x	n/a	US$701.0
HCAN.F Halo Collective	0.000007x	n/a	US$150.0
RVLP.Q RVL Pharmaceuticals	0.000007x	n/a	US$111.0
PLXP.Q PLx Pharma Winddown	0.000003x	n/a	US$30.0
GNRS Greenrose Holding	n/a	n/a	US$1.8k

Price-To-Book vs Peers: Insufficient data to calculate GNRS's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does GNRS's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

24 Companies	Price / Book	Estimated Growth	Market Cap

24 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: Insufficient data to calculate GNRS's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is GNRS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GNRS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GNRS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

BeiGene

US$21.9b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

BGNE

US$206.16

8.2%

10.0%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

2.5%

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

-0.2%

-7.1%